Company

Vivaldi Biosciences, Inc.

Vivaldi Biosciences develops vaccines for viral respiratory diseases using its Delta NS1 technology.

About

Vivaldi Biosciences develops vaccines for viral respiratory diseases using its Delta NS1 technology, including candidates for influenza and COVID-19. The company is based in New York, US, and its CEO is Bill Wick. Its Series A raised USD 18.85 mn from investors including Alexandria Venture Investments and Bay City Capital.

2Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in